Sunday April 28, 2024 | Last Update: April 28, 2024 EDT
GlaxoSmithKline Plc has just announced that it will be selling its rights in ofatumumab, a drug that treats autoimmune disease, including multiple sclerosis, to Novartis AG for more than $1.03 billion, according to a press release issued by Glaxo.
Read more >>
Just In
Most Read
1
2
3
4
5